|Bid||5.00 x 2200|
|Ask||8.00 x 400|
|Day's Range||7.27 - 7.58|
|52 Week Range||1.42 - 7.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Arrowhead Pharmaceuticals Inc. today announced that the company will make a presentation at the following upcoming event:
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent ...
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
Arrowhead Pharmaceuticals Inc. today announced the United States Food and Drug Administration has granted orphan drug designation to ARO-AAT, Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.
The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2018 first quarter ended December 31, 2017. The company is hosting a conference call at 4:30 p.m.
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR ) will be discussing their earnings results in their Q1 Earnings Call to be held on February 9, 2018 at 4:30 ...
Krishna Memani, chief investment officer of OppenheimerFunds, blasted passive investing in a video on the investment firm’s home page. “Conventional thinking has people believing there are only 500 great companies, and they’re all headquartered in the U.S.,” Memani declares, taking aim at the Standard & Poor’s 500 index, the standard-bearer of exchange-traded fund investing. The firm cut back on its Nektar Therapeutics (NKTR) position as the stock ended 2017 with a fivefold price increase.
Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal 2018 first quarter ended December 31, 2017.
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
Arrowhead Pharmaceuticals Inc. today announced that on January 22, 2018 it closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares.
Arrowhead Pharmaceuticals Inc. today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts.
Arrowhead Pharmaceuticals Inc. today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
Arrowhead Pharmaceuticals Inc. today announced that the board of directors elected veteran biotechnology executive William Waddill as an independent director of the company, with a term beginning effective January 1, 2018.
Categories: Yahoo FinanceGet free summary analysis Arrowhead Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Arrowhead Pharmaceuticals, Inc. – Alnylam Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Shire PLC Sponsored ADR, Ligand Pharmaceuticals Incorporated, Inovio Pharmaceuticals, Inc. and Abeona Therapeutics, Inc. (ALNY-US, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Arrowhead Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARWR-US. Comparing the performance and risk of Arrowhead Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)